Development of a chitosan‐modified PLGA nanoparticle vaccine for protection against Escherichia coli K1 caused meningitis in mice

Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has...

Full description

Saved in:
Bibliographic Details
Published inJournal of nanobiotechnology Vol. 19; no. 1; pp. 69 - 15
Main Authors Zhang, Jin, Sun, Hongwu, Gao, Chen, Wang, Ying, Cheng, Xin, Yang, Yun, Gou, Qiang, Lei, Langhuang, Chen, Yanping, Wang, Xingyong, Zou, Quanming, Gu, Jiang
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 05.03.2021
BioMed Central
BMC
Subjects
Acids
Aluminum
Antigens
Bacteremia
Care and treatment
Chitin
Chitosan
E coli
Efficiency
Escherichia coli
Escherichia coli K1
Ethics
Freeze drying
Glycolic acid
Health aspects
Immunization
Immunogenicity
Industrial applications
Meningitis
Microscopy
Nanoparticles
Neonates
PLGA
Polylactide-co-glycolide
Proteins
Size distribution
Stability
Vaccine
Vaccines
China
Beijing China
Japan
Nanoparticles
Vaccine
PLGA
Chitosan
Escherichia coli K1
Online AccessGet full text

Cover

Abstract Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application. Chitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia. We successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days. We identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1.
AbstractList Abstract Background Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application. Method Chitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia. Results We successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days. Conclusions We identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1.
Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application.BACKGROUNDEscherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application.Chitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia.METHODChitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia.We successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days.RESULTSWe successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days.We identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1.CONCLUSIONSWe identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1.
Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application. Chitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia. We successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days. We identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1.
Background Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application. Method Chitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia. Results We successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days. Conclusions We identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1.
Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application. Chitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia. We successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days. We identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1.
Background Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally designed and produced the recombinant protein OmpAVac (Vo), which elicited protective immunity against E. coli K1 infection. However, Vo has limited stability, which hinders its future industrial application. Method Chitosan-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared and used as carried for the recombinant Vo. And the safety, stability and immunogenicity of Vo delivered by chitosan-modified PLGA nanoparticles were tested in vitro and in a mouse model of bacteremia. Results We successfully generated chitosan-modified PLGA nanoparticles for the delivery of recombinant Vo (VoNP). In addition, we found that a freeze-drying procedure increases the stability of the VoNPs without changing the shape, size distribution and encapsulation of the Vo protein. Unlike aluminum adjuvant, the nanoparticles that delivered Vo were immunoprotective in mice even after storage for as long as 180 days. Conclusions We identified an effective strategy to improve the stability of Vo to maintain its immunogenicity, which will contribute to the future development of vaccines against E. coli K1. Keywords: Escherichia coli K1, Chitosan, PLGA, Nanoparticles, Vaccine
ArticleNumber 69
Audience Academic
Author Zhang, Jin
Zou, Quanming
Yang, Yun
Gou, Qiang
Sun, Hongwu
Wang, Ying
Cheng, Xin
Wang, Xingyong
Chen, Yanping
Gu, Jiang
Lei, Langhuang
Gao, Chen
Author_xml – sequence: 1
  givenname: Jin
  surname: Zhang
  fullname: Zhang, Jin
– sequence: 2
  givenname: Hongwu
  surname: Sun
  fullname: Sun, Hongwu
– sequence: 3
  givenname: Chen
  surname: Gao
  fullname: Gao, Chen
– sequence: 4
  givenname: Ying
  surname: Wang
  fullname: Wang, Ying
– sequence: 5
  givenname: Xin
  surname: Cheng
  fullname: Cheng, Xin
– sequence: 6
  givenname: Yun
  surname: Yang
  fullname: Yang, Yun
– sequence: 7
  givenname: Qiang
  surname: Gou
  fullname: Gou, Qiang
– sequence: 8
  givenname: Langhuang
  surname: Lei
  fullname: Lei, Langhuang
– sequence: 9
  givenname: Yanping
  surname: Chen
  fullname: Chen, Yanping
– sequence: 10
  givenname: Xingyong
  surname: Wang
  fullname: Wang, Xingyong
– sequence: 11
  givenname: Quanming
  surname: Zou
  fullname: Zou, Quanming
– sequence: 12
  givenname: Jiang
  orcidid: 0000-0001-8035-4551
  surname: Gu
  fullname: Gu, Jiang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33673858$$D View this record in MEDLINE/PubMed
BookMark eNp9ksuO0zAUhiM0iLnAC7BAltjAIkN8SeJskKphGCoqgbisLd-SukrtYrsV7JB4AZ6RJ-F0WobpCKEoSmJ__39yjv_T4sgHb4viMa7OMebNi4RJV-OyInBXHJOyu1ecYNa2JcV1fXTr_bg4TWlRVYQwwh4Ux5Q2LeU1Pyl-vLIbO4bV0vqMQo8k0nOXQ5L-1_efy2Bc76xB72dXE-SlDysZs9OjRRuptfMW9SGiVQzZ6uyCR3KQzqeMLpOe2-jACwzD6NBbjLRcJ_CCSs4PLruEnEdLp-3D4n4vx2Qf7Z9nxefXl58u3pSzd1fTi8ms1HXX5pKqrulVyzqlMGVcUoVbbYw1pCG21cpWUhusjNLSbLe0qnXTSE5rjUHI6Vkx3fmaIBdiFd1Sxm8iSCeuF0IcxL49QbDuuOYUulQM15xDBUuUsfChKqLB6-XOa7VWS2s0jC_K8cD0cMe7uRjCRrQdZazqwODZ3iCGL2ubsli6pO04Sm_DOgnCOs447UgD6NM76CKso4dRCVJXhLOWUPqXGiQ04HwfoK7emopJU9eE1h1jQJ3_g4LLWDgKyFfvYP1A8PxAAEy2X_MAh5nE9OOHQ_bJ7aHcTONP3AAgO0DHkFK0_Q2CK7HNtNhlWkCmxXWmxXZS_I5Iuyy3cYNfd-P_pL8BsUD8rw
CitedBy_id crossref_primary_10_3390_pharmaceutics16091155
crossref_primary_10_7717_peerj_15523
crossref_primary_10_1016_j_mattod_2023_08_005
crossref_primary_10_1186_s12951_024_03066_3
crossref_primary_10_1016_j_ejpb_2024_114326
crossref_primary_10_3390_ijms241310580
crossref_primary_10_2174_1570180820666230214091500
crossref_primary_10_1016_j_ijbiomac_2025_141709
crossref_primary_10_3390_biomimetics10010025
crossref_primary_10_1038_s41467_024_46775_x
crossref_primary_10_1080_17425247_2024_2400293
crossref_primary_10_2174_1381612828666220728092336
crossref_primary_10_3390_pharmaceutics15020615
crossref_primary_10_1021_acsami_4c01384
crossref_primary_10_1002_mba2_62
crossref_primary_10_1016_j_ijbiomac_2022_01_175
crossref_primary_10_1016_j_xinn_2023_100503
crossref_primary_10_3390_pharmaceutics13111913
crossref_primary_10_1021_acsanm_2c01380
crossref_primary_10_12677_acm_2024_1441067
crossref_primary_10_1016_j_ijbiomac_2023_127278
crossref_primary_10_1080_19490976_2024_2359691
crossref_primary_10_3390_ijms231810975
Cites_doi 10.1016/j.micinf.2014.06.002
10.1080/21645515.2015.1117714
10.1016/S0952-7915(03)00083-9
10.12688/f1000research.8533.1
10.3389/fped.2017.00139
10.1016/j.ijpharm.2009.07.023
10.1111/j.1742-4658.2012.08482.x
10.1016/S0140-6736(83)90340-9
10.1016/j.ejpb.2013.06.017
10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
10.1016/j.jconrel.2012.01.043
10.1002/jbm.b.33648
10.3390/vaccines2030515
10.1016/S1474-4422(18)30387-9
10.1016/j.ijpharm.2019.118739
10.1371/journal.pone.0198772
10.2174/138161210793292447
10.3390/polym11020304
10.1093/jac/dkr235
10.1016/j.micres.2015.10.004
10.1097/QCO.0b013e3283521eb0
10.1038/ncomms1554
10.1006/jmbi.2000.3671
10.1007/s10156-011-0232-3
10.1016/j.biomaterials.2014.05.067
10.1080/1061186X.2018.1512112
10.1080/07373937.2019.1653906
10.1093/infdis/jis656
10.1080/21645515.2015.1094595
10.1128/IAI.00953-15
10.1111/cas.12050
10.2217/nnm-2018-0147
10.1016/j.msec.2017.12.036
10.1111/ped.14108
10.3389/fcimb.2018.00172
10.1089/mab.2012.0069
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
NPM
ISR
3V.
7QO
7TB
7X7
7XB
88E
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB.
LK8
M0S
M1P
M7P
P64
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12951-021-00812-9
DatabaseName CrossRef
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Mechanical & Transportation Engineering Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
ProQuest One
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
Materials Science Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Mechanical & Transportation Engineering Abstracts
ProQuest Central Essentials
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
Materials Science Database
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Materials Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

Publicly Available Content Database

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1477-3155
EndPage 15
ExternalDocumentID oai_doaj_org_article_21c98c83accb415882e7e2bde415b02c
PMC7934409
A655235944
33673858
10_1186_s12951_021_00812_9
Genre Journal Article
GeographicLocations China
Beijing China
Japan
GeographicLocations_xml – name: China
– name: Beijing China
– name: Japan
GrantInformation_xml – fundername: Natural Science Foundation of Chongqing (CN)
  grantid: CSTC2020JCYJ-MSXM2301
– fundername: National Natural Science Foundation of China
  grantid: 81772155
– fundername: ;
  grantid: 81772155
– fundername: ;
  grantid: CSTC2020JCYJ-MSXM2301
GroupedDBID ---
0R~
29L
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADDVE
ADMLS
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D1I
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
I-F
IAO
IHR
INH
INR
ISR
ITC
ITG
ITH
KB.
KQ8
LK8
M1P
M48
M7P
MM.
M~E
O5R
O5S
OK1
OVT
P2P
PDBOC
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
RVI
SCM
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
NPM
PMFND
3V.
7QO
7TB
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c597t-3b96fb749bb1348a3b17cdded262e7cbe0acd1bdbcadb17ccb5c66a835c16fb83
IEDL.DBID M48
ISSN 1477-3155
IngestDate Wed Aug 27 01:21:50 EDT 2025
Thu Aug 21 18:45:48 EDT 2025
Fri Jul 11 09:07:01 EDT 2025
Fri Jul 25 19:21:58 EDT 2025
Tue Jun 17 21:09:42 EDT 2025
Tue Jun 10 20:28:15 EDT 2025
Fri Jun 27 04:00:18 EDT 2025
Thu Apr 03 07:04:04 EDT 2025
Tue Jul 01 01:26:45 EDT 2025
Thu Apr 24 22:57:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Nanoparticles
Vaccine
PLGA
Chitosan
Escherichia coli K1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c597t-3b96fb749bb1348a3b17cdded262e7cbe0acd1bdbcadb17ccb5c66a835c16fb83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8035-4551
OpenAccessLink https://doaj.org/article/21c98c83accb415882e7e2bde415b02c
PMID 33673858
PQID 2502847233
PQPubID 44676
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_21c98c83accb415882e7e2bde415b02c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7934409
proquest_miscellaneous_2498483926
proquest_journals_2502847233
gale_infotracmisc_A655235944
gale_infotracacademiconefile_A655235944
gale_incontextgauss_ISR_A655235944
pubmed_primary_33673858
crossref_primary_10_1186_s12951_021_00812_9
crossref_citationtrail_10_1186_s12951_021_00812_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-03-05
PublicationDateYYYYMMDD 2021-03-05
PublicationDate_xml – month: 03
  year: 2021
  text: 2021-03-05
  day: 05
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of nanobiotechnology
PublicationTitleAlternate J Nanobiotechnology
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References A Rezvankhah (812_CR17) 2020; 38
A Pautsch (812_CR10) 2000; 298
J Finne (812_CR20) 1983; 322
AM Oordt-Speets (812_CR2) 2018; 13
AL Silva (812_CR13) 2016; 12
MV Shanmuganathan (812_CR35) 2013; 207
H Gu (812_CR12) 2018; 8
S Krishnan (812_CR7) 2014; 16
812_CR32
D Ding (812_CR15) 2018; 92
GBDM Collaborators (812_CR4) 2018; 17
S Eliyahu (812_CR33) 2020; 573
812_CR3
D Pawar (812_CR31) 2013; 85
T Yamamoto (812_CR18) 2011; 17
LA Witcomb (812_CR36) 2015; 83
S Krishnan (812_CR5) 2012; 279
Y Abe (812_CR8) 2013; 32
L Dudek (812_CR22) 2010; 16
H Wang (812_CR11) 2016; 182
B Lu (812_CR30) 2019; 11
SM Gordon (812_CR1) 2017; 5
R Wen (812_CR27) 2019; 14
R Mittal (812_CR6) 2011; 2
K Tahara (812_CR34) 2009; 382
A Yamada (812_CR23) 2013; 104
A Sette (812_CR26) 2003; 15
Q Wang (812_CR29) 2014; 35
W Li (812_CR24) 2014; 2
J Blanco (812_CR19) 2011; 66
P Oyarzún (812_CR25) 2016; 12
KS Kim (812_CR21) 2012; 25
Y Xu (812_CR28) 2017; 105
F Danhier (812_CR14) 2012; 161
SY Ahn (812_CR37) 2020; 62
S Naskar (812_CR16) 2019; 27
H Gu (812_CR9) 2018; 8
References_xml – volume: 16
  start-page: 540
  year: 2014
  ident: 812_CR7
  publication-title: Microb Infect
  doi: 10.1016/j.micinf.2014.06.002
– volume: 12
  start-page: 1056
  year: 2016
  ident: 812_CR13
  publication-title: Hum Vaccin Immunother
  doi: 10.1080/21645515.2015.1117714
– volume: 15
  start-page: 461
  year: 2003
  ident: 812_CR26
  publication-title: Curr Opin Immunol
  doi: 10.1016/S0952-7915(03)00083-9
– ident: 812_CR3
  doi: 10.12688/f1000research.8533.1
– volume: 5
  start-page: 139
  year: 2017
  ident: 812_CR1
  publication-title: Front Pediatr
  doi: 10.3389/fped.2017.00139
– volume: 382
  start-page: 198
  year: 2009
  ident: 812_CR34
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2009.07.023
– volume: 279
  start-page: 919
  year: 2012
  ident: 812_CR5
  publication-title: FEBS J
  doi: 10.1111/j.1742-4658.2012.08482.x
– volume: 322
  start-page: 355
  year: 1983
  ident: 812_CR20
  publication-title: Lancet
  doi: 10.1016/S0140-6736(83)90340-9
– volume: 85
  start-page: 550
  year: 2013
  ident: 812_CR31
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2013.06.017
– ident: 812_CR32
  doi: 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
– volume: 161
  start-page: 505
  year: 2012
  ident: 812_CR14
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2012.01.043
– volume: 105
  start-page: 1692
  year: 2017
  ident: 812_CR28
  publication-title: J Biomed Mater Res Part B Appl Biomater
  doi: 10.1002/jbm.b.33648
– volume: 2
  start-page: 515
  year: 2014
  ident: 812_CR24
  publication-title: Vaccines
  doi: 10.3390/vaccines2030515
– volume: 17
  start-page: 1061
  year: 2018
  ident: 812_CR4
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(18)30387-9
– volume: 573
  start-page: 118739
  year: 2020
  ident: 812_CR33
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2019.118739
– volume: 13
  start-page: e0198772
  year: 2018
  ident: 812_CR2
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0198772
– volume: 16
  start-page: 3149
  year: 2010
  ident: 812_CR22
  publication-title: Curr Pharm Des
  doi: 10.2174/138161210793292447
– volume: 11
  start-page: 304
  year: 2019
  ident: 812_CR30
  publication-title: Polymers
  doi: 10.3390/polym11020304
– volume: 66
  start-page: 2011
  year: 2011
  ident: 812_CR19
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr235
– volume: 182
  start-page: 109
  year: 2016
  ident: 812_CR11
  publication-title: Microbiol Res
  doi: 10.1016/j.micres.2015.10.004
– volume: 25
  start-page: 273
  year: 2012
  ident: 812_CR21
  publication-title: Curr Opin Infect Dis
  doi: 10.1097/QCO.0b013e3283521eb0
– volume: 2
  start-page: 552
  year: 2011
  ident: 812_CR6
  publication-title: Nat Commun
  doi: 10.1038/ncomms1554
– volume: 298
  start-page: 273
  year: 2000
  ident: 812_CR10
  publication-title: J Mol Biol
  doi: 10.1006/jmbi.2000.3671
– volume: 17
  start-page: 435
  year: 2011
  ident: 812_CR18
  publication-title: J Infect Chemother
  doi: 10.1007/s10156-011-0232-3
– volume: 35
  start-page: 8385
  year: 2014
  ident: 812_CR29
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2014.05.067
– volume: 27
  start-page: 379
  year: 2019
  ident: 812_CR16
  publication-title: J Drug Target
  doi: 10.1080/1061186X.2018.1512112
– volume: 38
  start-page: 235
  year: 2020
  ident: 812_CR17
  publication-title: Dry Technol
  doi: 10.1080/07373937.2019.1653906
– volume: 207
  start-page: 61
  year: 2013
  ident: 812_CR35
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jis656
– volume: 12
  start-page: 763
  year: 2016
  ident: 812_CR25
  publication-title: Hum Vaccines Immunother
  doi: 10.1080/21645515.2015.1094595
– volume: 83
  start-page: 4528
  year: 2015
  ident: 812_CR36
  publication-title: Infect Immun
  doi: 10.1128/IAI.00953-15
– volume: 104
  start-page: 15
  year: 2013
  ident: 812_CR23
  publication-title: Cancer Sci
  doi: 10.1111/cas.12050
– volume: 14
  start-page: 627
  year: 2019
  ident: 812_CR27
  publication-title: Nanomedicine
  doi: 10.2217/nnm-2018-0147
– volume: 92
  start-page: 1041
  year: 2018
  ident: 812_CR15
  publication-title: Mater Sci Eng C
  doi: 10.1016/j.msec.2017.12.036
– volume: 62:
  start-page: 347
  year: 2020
  ident: 812_CR37
  publication-title: Pediatr Int
  doi: 10.1111/ped.14108
– volume: 8
  start-page: 172
  year: 2018
  ident: 812_CR9
  publication-title: Front Cell Infect Microbiol
  doi: 10.3389/fcimb.2018.00172
– volume: 8
  start-page: 172
  year: 2018
  ident: 812_CR12
  publication-title: Front Cell Infect Microbiol
  doi: 10.3389/fcimb.2018.00172
– volume: 32
  start-page: 32
  year: 2013
  ident: 812_CR8
  publication-title: Monoclon Antib Immunodiagn Immunother
  doi: 10.1089/mab.2012.0069
SSID ssj0022424
Score 2.4029
Snippet Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we rationally...
Background Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine. Previously, we...
Abstract Background Escherichia coli K1 (E. coli K1) caused neonatal meningitis remains a problem, which rises the urgent need for an effective vaccine....
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 69
SubjectTerms Acids
Aluminum
Antigens
Bacteremia
Care and treatment
Chitin
Chitosan
E coli
Efficiency
Escherichia coli
Escherichia coli K1
Ethics
Freeze drying
Glycolic acid
Health aspects
Immunization
Immunogenicity
Industrial applications
Meningitis
Microscopy
Nanoparticles
Neonates
PLGA
Polylactide-co-glycolide
Proteins
Size distribution
Stability
Vaccine
Vaccines
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtQwDI7QnuCA-KewoICQOKBq27RNm-OAdll-hYCV9hYlbrtbCVpEZzgj8QI8I0_C57YzaoUEFw5zmInjTmwntmecz0I8IpM551UZZpUmBtWOQ5-SD7XLXZbXBl6Rf4d881Yfn6QvT7PTWasvrgkb4YFHwR2omExBReKIPJwNAsIqr5QvK7zxkSI-feHztsnUlGrxpYftFZlCH_TwahnSZoUXfKAKzcINDWj9f57JM6e0LJiceaCjK-LyFDrK1fiVr4oLVXtNXJoBCl4XP2Y1QLKrpZP8N0HXu_bX95-fu7KpEXHKd6-fr2TrWuTLIy_5DesGF4kIVk7IDdCXdGeuQfgoD3tWbcNl0RKG08hXsSS36cELTxpaHjW9bFrJve1viJOjw4_PjsOpzUJIyCbWYeKNrn2eGu_jJC1c4uOccOqVSkPW5KvIURn70pMreYh8Rlo7hG4UY2KR3BR7bddWt4U0ESYVTuWaGKMUCo9iAk8dUwQuRSDirdQtTRjk3Arjkx1ykULbUVMWmrKDpqwJxJPdnC8jAsdfqZ-yMneUjJ49fACbspNQ7b9sKhAP2RQs42O0XIBzBpH29sWH93alM6TumUnTQDyeiOoOayA33WeAJBhSa0G5v6DEBqbl8Nbi7HSA9BaRKQcOKkkC8WA3zDO5KK6tug1oUlOkHODqQNwaDXS37iTRA05RIPKF6S4Esxxpm_MBXhwndoqs_87_kORdcVENu46LRPfF3vrrprqHKG7t7w8b9jewb0Zt
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXOCAeJNSkEFIHFDU2Emc-IQW1FKeQkClvVn2xFki0aQ0u5yR-AP8Rn4JM4l3uxFSD3vY9djZzNjzsMffMPYUdG6tk1WcewUEqi1il4GLlS1sXtQarSLtQ374qI6Os7fzfB423PqQVrnWiYOirjqgPfJ9NNWkSWWavjj9EVPVKDpdDSU0LrMrBF1GKV3F_DzgoqsP64sypdrv0bblGDxL_KAllLGeGKMBs_9_zbxlmqZpk1t26PAGux4cSD4bJX6TXfLtLXZtC1bwNvu9lQnEu5pbTocFXW_bv7_-nHRVU6PfyT-9fz3jrW0xah7H4j8t0DE7Rz-WB_wGlBq3C9ugE8kPehJwQ8nRHKdPw98JDnbV41j4pKHwUdPzpuVU4f4OOz48-PrqKA7FFmLAmGIZp06r2hWZdk6kWWlTJwpA3VdJJX0BzicWKuEqB7aiJnA5KGXRgQOBHcv0Lttpu9bfZ1wn2Km0slBASKUo9kQAjqkEJDhKGTGx5rqBgEROBTG-myEiKZUZJWVQUmaQlNERe77pczricFxI_ZKEuaEkDO3hh-5sYQJTjRSgSyhT5K1DNwZDDV946SqPX1wiIWJPaCoYQsloKQ1ngSztzZsvn81M5RjA5zrLIvYsENUdvgPYcKsBOUHAWhPKvQklLmOYNq9nnAlqpDfnkz5ijzfN1JNS41rfrZAm02VGbq6K2L1xgm7eO03VgFYUsWIydSeMmba0zbcBZBz1doax_-7Ff-sBuyqH9URJoHtsZ3m28g_RS1u6R8NS_AfcXD1-
  priority: 102
  providerName: ProQuest
Title Development of a chitosan‐modified PLGA nanoparticle vaccine for protection against Escherichia coli K1 caused meningitis in mice
URI https://www.ncbi.nlm.nih.gov/pubmed/33673858
https://www.proquest.com/docview/2502847233
https://www.proquest.com/docview/2498483926
https://pubmed.ncbi.nlm.nih.gov/PMC7934409
https://doaj.org/article/21c98c83accb415882e7e2bde415b02c
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELb2cYED4r2BpTIIiQMKJI5jxweEuqjd5bGr1UKl3izbSUqk3QSaFsGRf86Mm1aNWCEOrdR67Cjz8MzY48-EPHcqNcayPEwL4RBUOw4tdzYURppUlgq8Iq5Dnp6Jkwn_ME2nO2R93VHHwPba1A7vk5rML1_9_P7rLRj8G2_wmXjdgs9KISlm8AEPx0K1S_bBM0k01FO-2VVgeBTCnzaSuDaXputDNNeO0XNUHs__71l7y231Syq3fNT4NrnVBZd0uNKGO2SnqO-Sm1uQg_fI760qIdqU1FDcSGhaU4dXTV6VEJHS80_HQ1qbGvLp1Uj0h3G4AU8hwqUdsgPIk5qZqSC8pKMWRV9h2TQFxarox5g6s2xhLHiOvxKpamlV0yuYlu6TyXj05d1J2F3DEDrINhZhYpUoreTK2jjhmUlsLB3MijkTrJDOFpFxeWxz60yOTc6mTggDoZ2LoWOWPCB7dVMXB4SqCDplhknhEMMUFCKKHYwpYhfBKFlA4jXPteswyvGqjEvtc5VM6JWcNMhJezlpFZCXmz7fVggd_6Q-QlFuKBFd2__RzGe6Y6pmsVOZyxLgrYUAB5KQQhbM5gX8sBFzAXmGiqARP6PGAp0ZsLTV7z9f6KFIIbVPFecBedERlQ28gzPdeQfgBEJu9SgPe5Rg4K7fvNY3vbYPDZErBhYsSQLydNOMPbFori6aJdBwlXEMgEVAHq7Uc_PeSSI8jlFAZE9xe4zpt9TVVw8_DjM655F69B_PfUxuMG9SWCN6SPYW82XxBIK4hR2QXTmV8J2Njwdk_2h0dn4x8AsiA2-zfwAyoUc3
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VcgAOiH8MBRYE4oCs2mt77T0gFKClIWmFoJVy2-6OnWCJ2qVOQNyQeAGehIfiSZjxTxoLqbceckh2dh3PzM6PPfsNY09BRcZYkbpRJoFAtX3XhmBdaWITxVOFXpGeQ-7uyZ2D8P0kmqyxP91ZGCqr7GxibajTEugZ-Sa6arKkIgheHX91qWsUvV3tWmg0ajHKfnzHlK16OXyL8n0mxPbW_psdt-0q4AIGz3M3sEpObRwqa_0gTExg_Rhwk6dCiiwGm3kGUt-mFkxKQ2AjkNJgpAI-TkwCXPcCu4iO16MdFU9OEzw6atEdzEnkZoW-NMJkXeAHPa9wVc_51T0C_vcEK66wX6a54ve2r7GrbcDKB42GXWdrWXGDXVmBMbzJfq1UHvFyyg2nlxNlZYq_P38flWk-xTiXfxi_G_DCFJilN2vxbwbotT7HuJm3eBGoJdzMTI5BK9-qSKFyKsbmqK45H_kczKLCtfBKdaOlvOJ5wY_Q2N1iB-cihttsvSiL7C7jysNJiRGxBEJGRTXzfMA1pQ8erpI4zO-4rqFFPqcGHF90nQElUjeS0igpXUtKK4e9WM45bnA_zqR-TcJcUhJmd_1DeTLTLVO18EElkATIW4thE6Y2WZwJm2b4xXoCHPaEVEETKkdBZT8zZGmlh58-6oGMIhFEKgwd9rwlmpZ4D2DaUxTICQLy6lFu9CjRbEB_uNM43ZqtSp9uMoc9Xg7TTCrFK7JygTShSkIKq6XD7jQKurzvIJA1OpLD4p7q9hjTHynyzzWoOfqJMPTUvbP_1iN2aWd_d6zHw73RfXZZ1HuLClA32Pr8ZJE9wAhxbh_W25Kzw_O2A_8AJX99xQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+chitosan-modified+PLGA+nanoparticle+vaccine+for+protection+against+Escherichia+coli+K1+caused+meningitis+in+mice&rft.jtitle=Journal+of+nanobiotechnology&rft.au=Zhang%2C+Jin&rft.au=Sun%2C+Hongwu&rft.au=Gao%2C+Chen&rft.au=Wang%2C+Ying&rft.date=2021-03-05&rft.issn=1477-3155&rft.eissn=1477-3155&rft.volume=19&rft.issue=1&rft.spage=69&rft_id=info:doi/10.1186%2Fs12951-021-00812-9&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-3155&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-3155&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-3155&client=summon